Obesity and Weight Gain Are Associated With Progression of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Background & Aims The effects of weight change on the progression of liver fibrosis in patients with nonalcoholic fatty liver disease (NAFLD) in the general population are unclear. We evaluated the association of weight change and baseline body mass index (BMI) with fibrosis progression, determined by non‐invasive measurement of a marker, in young and middle‐aged adults with NAFLD. Methods We performed a prospective cohort study of 40,700 adults with NAFLD in Korea who received regular health screening examinations and were followed for a median 6.0 years. Weight change was defined as the difference between weights measured at baseline and at a subsequent follow‐up visit. The progression from a low to an intermediate or high probability of advanced fibrosis was assessed using the aspartate aminotransferase to platelet ratio index (APRI). Results During 275,421.5 person‐years of follow‐up, 5454 subjects with a low APRI progressed to an intermediate or high APRI. Multivariable‐adjusted hazard ratios for APRI progression, determined by comparing the first and second weight change quintiles (the weight‐loss group) and the fourth and fifth quintiles (weight‐gain group) with the third quintile (weight‐stable group, reference), were 0.68 (95% CI, 0.62–0.74), 0.86 (95% CI, 0.78–0.94), 1.17 (95% CI, 1.07–1.28), and 1.71 (95% CI, 1.58–1.85), respectively. The multivariable‐adjusted hazard ratios for APRI progression were determined by comparing subjects with BMIs of 23–24.9, 25–29.9, and ≥30 with subjects with BMIs of 18.5–22.9 kg/m2 (reference); these ratios were 1.13 (95% CI, 1.02–1.26), 1.41 (95% CI, 1.28–1.55), and 2.09 (95% CI, 1.86–2.36), respectively. Conclusions In a prospective cohort study of 40,700 adults with NAFLD, we found obesity and weight gain to be independently associated with increased risk of fibrosis progression, based on APRI. Maintaining a normal healthy weight and preventing weight gain may help reduce fibrosis progression in individuals with NAFLD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mechanisms linking obesity to insulin resistance and type 2 diabetes
Kahn, S. E., Hull, R. L., & Utzschneider, K. M. (2006) · Nature · doi:10.1038/nature05482 · Cited by 5,448
Angulo, P., Kleiner, D. E., Dam-Larsen, S., Adams, L. A., Bjornsson, E. S., Charatcharoenwitthaya, P., Mills, P. R., Keach, J. C., Lafferty, H. D., Stahler, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.043 · Cited by 2,987
Long-term follow-up of patients with NAFLD and elevated liver enzymes
Ekstedt, M., Franzén, L. E., Mathiesen, U. L., Thorelius, L., Holmqvist, M., Bodemar, G., & Kechagias, S. (2006) · Hepatology · doi:10.1002/hep.21327 · Cited by 2,302
Ekstedt, M., Hagström, H., Nasr, P., Fredrikson, M., Stål, P., Kechagias, S., & Hultcrantz, R. (2015) · Hepatology · doi:10.1002/hep.27368 · Cited by 2,287
Dulai, P. S., Singh, S., Patel, J., Soni, M., Prokop, L. J., Younossi, Z., Sebastiani, G., Ekstedt, M., Hagstrom, H., Nasr, P., et al. (2017) · Hepatology · doi:10.1002/hep.29085 · Cited by 1,965
Singh, S., Allen, A. M., Wang, Z., Prokop, L. J., Murad, M. H., & Loomba, R. (2015) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.04.014 · Cited by 1,748
Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis
Promrat, K., Kleiner, D. E., Niemeier, H. M., Jackvony, E., Kearns, M., Wands, J. R., Fava, J. L., & Wing, R. R. (2010) · Hepatology · doi:10.1002/hep.23276 · Cited by 1,330
Neuschwander‐Tetri, B. A. (2010) · Hepatology · doi:10.1002/hep.23719 · Cited by 1,077
Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight loss
Dixon, J. B., Bhathal, P. S., Hughes, N. R., & O'Brien, P. E. (2004) · Hepatology · doi:10.1002/hep.20251 · Cited by 727
Harrison, S. A., Fecht, W., Brunt, E. M., & Neuschwander‐Tetri, B. A. (2009) · Hepatology · doi:10.1002/hep.22575 · Cited by 470
Cited by
Lonardo, A., Nascimbeni, F., Ballestri, S., Fairweather, D., Win, S., Than, T. A., Abdelmalek, M. F., & Suzuki, A. (2019) · Hepatology · doi:10.1002/hep.30626 · Cited by 1,050
Metabolic dysfunction-associated steatotic liver disease in adults
Huang, D. Q., Wong, V. W. S., Rinella, M. E., Boursier, J., Lazarus, J. V., Yki-Järvinen, H., & Loomba, R. (2025) · Nature Reviews Disease Primers · doi:10.1038/s41572-025-00599-1 · Cited by 293
Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis
Lee, K.-C., Wu, P.-S., & Lin, H.-C. (2023) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0237 · Cited by 246
Koutoukidis, D. A., Koshiaris, C., Henry, J. A., Noreik, M., Morris, E., Manoharan, I., Tudor, K., Bodenham, E., Dunnigan, A., Jebb, S. A., et al. (2021) · Metabolism · doi:10.1016/j.metabol.2020.154455 · Cited by 186
AGA Clinical Practice Update on Bariatric Surgery in Cirrhosis: Expert Review
Patton, H., Heimbach, J., & McCullough, A. (2021) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2020.10.034 · Cited by 97
Simon, T. G., Kim, M. N., Luo, X., Yang, W., Ma, Y., Chong, D. Q., Fuchs, C. S., Meyerhardt, J. A., Corey, K. E., Chung, R. T., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.12.022 · Cited by 57
Bajaj, H. S., Burrows, M., Blavignac, J., Paron, E., Camacho, F., Gould, E., & Barakat, M. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14284 · Cited by 28
“Theoretically, similar to lifestyle modifications, antiobesity pharmacotherapy options have the potential to reduce liver fat, especially in the early stages of NAFLD.”
BackgroundModeling the health and economic impact of pharmacologic therapies for MASLD in the United States
Wallace, C., Gamkrelidze, I., Estes, C., Razavi, H., & Sanyal, A. J. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.01.009 · Cited by 27
Chronic liver diseases and erectile dysfunction
Zang, G., Sun, X., Sun, Y., Zhao, Y., Dong, Y., Pang, K., Cheng, P., Wang, M., & Zheng, Y. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2022.1092353 · Cited by 21
“The main reason may be that NAFLD and ED share common risk factors such as obesity, hypertension, and diabetes mellitus (15, 16).”
BackgroundCurci, R., Bianco, A., Franco, I., Bonfiglio, C., Campanella, A., Mirizzi, A., Giannuzzi, V., Cozzolongo, R., Veronese, N., & Osella, A. R. (2023) · Nutrients · doi:10.3390/nu15163520 · Cited by 11
“In obese subjects, an improvement of fibrosis has been shown with weight loss [8]; weight is considered an independent predictor for progression of steatosis to liver fibrosis in NAFLD [10].”
Background
Metadata
- Authors
- Kim, Y., Chang, Y., Cho, Y. K., Ahn, J., Shin, H., & Ryu, S.
- Venue
- Clinical Gastroenterology and Hepatology
- Publisher
- Elsevier BV
- Published
- 2019-02
- Volume
- 17
- Issue
- 3
- Pages
- 543-550.e2
- ISSN
- 1542-3565 (ISSN-L)
- OpenAlex
- W2884734727
- Cited by
- 79
- References
- 11
- FWCI
- 5.28
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.